What does “unapproved new drug” mean in an FDA letter?

Short answer · as of 2026-10-05

FDA letters use “unapproved new drug” for a drug that is a “new drug” under the FD&C Act and has no effective FDA approval. The statutes do not use that exact phrase. It combines three sections: 201(p) defines a new drug, 505(a) bars introducing a new drug into interstate commerce without an effective approval, and 301(d) prohibits introducing it in violation of 505. These are FDA's allegations in a letter, not a court finding.

By Peptide Industry Gossip · Published · General explanation, not legal or medical advice. Disclaimer.

The three sections

  • Section 201(p), 21 U.S.C. 321(p): a “new drug” is a drug (other than for animals) whose composition is not generally recognized, among qualified experts, as safe and effective for the uses in its labeling. The statute has a grandfather clause for some older drugs.
  • Section 505(a), 21 U.S.C. 355(a): no one may introduce a new drug into interstate commerce unless an FDA approval of an application for it is effective.
  • Section 301(d), 21 U.S.C. 331(d): it is prohibited to introduce into interstate commerce an article in violation of several sections, including 505.

How the phrase gets used

The warning letters in our index, such as the Xcel Research, Pinnacle and Wholesale Peptide letters, cite sections 201(g)(1), 201(p), 301(d) and 505(a). Section 201(g)(1) defines a drug by its intended use, so the letters first argue the product is a drug, then that it is a new drug, then that it has no approval. See our research-use-only explainer for the intended-use step.

What it does not mean

  • It is not a statement that a product is unsafe or ineffective. It says the product lacks FDA approval.
  • It is not a court finding. A warning letter is informal and advisory, per FDA's manual.
  • Compounded drugs are also not FDA-approved, but they are addressed by separate conditions in sections 503A and 503B. See our comparison.

Sources

Quotes are from the FDA documents above, retrieved Oct. 5, 2026. FDA can revise those pages. See something wrong? Request a correction.

Related